Justin M. Balko

30.2k citations

152 papers · 11.5k indexed · 8 hit papers · h-index 50

Oncology top 0.2%
Molecular Biology top 1%
Immunology top 0.5%
Cancer Research top 0.5%
Pulmonary and Respiratory Medicine top 1%

Co-authors: Melinda E. Sanders Ingrid A. Mayer Douglas B. Johnson Giampaolo Bianchini Luca Gianni Carlos L. Arteaga Javid J. Moslehi Todd W. Miller
Topics: Cancer Immunotherapy and Biomarkers (51 papers)Cancer Genomics and Diagnostics (28 papers)PI3K/AKT/mTOR signaling in cancer (21 papers)
Cited by: Oncology Cancer Research Immunology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Circulation
Partner nations: United States Peru Australia

In The Last Decade

Justin M. Balko

143 papers receiving 11.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

2016 2.1k citations Justin M. Balko, Ingrid A. Mayer et al. profile →
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

2018 836 citations Joe‐Elie Salem, Ali Manouchehri et al. profile →
Immune-checkpoint inhibitors: long-term implications of toxicity

2022 610 citations Douglas B. Johnson, Javid J. Moslehi et al. profile →
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

2019 540 citations Douglas B. Johnson, Justin M. Balko et al. profile →
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

2017 479 citations Kyung‐min Lee, Jennifer M. Giltnane et al. profile →
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

2013 475 citations Neil E. Bhola, Justin M. Balko et al. profile →
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

2019 260 citations Douglas B. Johnson, Ali Manouchehri et al. Journal for ImmunoTherapy of Cancer profile →
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response

2022 153 citations Brandie C. Taylor, Justin M. Balko profile →

Peers

Countries citing papers authored by Justin M. Balko

Since Specialization

Citations

This map shows the geographic impact of Justin M. Balko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin M. Balko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin M. Balko more than expected).

Fields of papers citing papers by Justin M. Balko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin M. Balko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin M. Balko. The network helps show where Justin M. Balko may publish in the future.

Co-authorship network of co-authors of Justin M. Balko

This figure shows the co-authorship network connecting the top 25 collaborators of Justin M. Balko. A scholar is included among the top collaborators of Justin M. Balko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin M. Balko. Justin M. Balko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EMP2 Serves as a Functional Biomarker for Chemotherapy-Resistant Triple-Negative Breast Cancer 2024 ·Cancers ·Ann M. Chan,(unknown),(unknown),Vei Mah,Justin M. Balko,Jessica Tsui,(unknown),Neda A. Moatamed,(unknown),(unknown),(unknown),Yahya Elshimali,Helena R. Chang,Diana C. Márquez‐Garbán,Nalo Hamilton,Richard J. Pietras,Lynn K. Gordon,Madhuri Wadehra	3
2	No rest for the wicked: Tumor cell senescence reshapes the immune microenvironment 2023 ·Cancer Cell ·Ann Hanna,Justin M. Balko	8
3	Peripheral T-cell receptor repertoire dynamics in small cell lung cancer 2023 ·Translational Lung Cancer Research ·(unknown),Margaret L. Axelrod,Justin M. Balko,Armand Bankhead,Tristan Shaffer,Lee Yong Lim,Jiannan Guo,Jennifer Hernandez,Mark Li,Wade T. Iams	3
4	NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer 2023 ·Cancer Discovery ·Brandie C. Taylor,Xiaopeng Sun,Paula I. González-Ericsson,Violeta Sánchez,Melinda E. Sanders,(unknown),Susan R. Opalenik,Ann Hanna,(unknown),Luc Van Kaer,Henry Gómez,Claudine Isaacs,Tarah J. Ballinger,Cesar A. Santa‐Maria,Payal D. Shah,Elizabeth Claire Dees,Brian D. Lehmann,Vandana G. Abramson,Jennifer A. Pietenpol,Justin M. Balko	31
5	Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities 2023 ·Immunological Reviews ·Rachel Goodman,(unknown),Justin M. Balko,Douglas B. Johnson	16
6	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer 2022 ·Cancer Research Communications ·Margaret L. Axelrod,Yu Wang,Yaomin Xu,Xiaopeng Sun,Cosmin A. Bejan,Paula I. González-Ericsson,Sara Nunnery,(unknown),Joshua Donaldson,Ángel Guerrero‐Zotano,Chiara Massa,Barbara Seliger,Melinda E. Sanders,Ingrid A. Mayer,Justin M. Balko	5
7	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer 2021 ·Clinical Cancer Research ·Paula I. González-Ericsson,(unknown),Rosa I. Gallagher,Xiaopeng Sun,Margaret L. Axelrod,Quanhu Sheng,Na Luo,Henry Gómez,Violeta Sánchez,Melinda E. Sanders,Lajos Pusztai,Emanuel Petricoin,Kim Blenman,Justin M. Balko,(unknown)	54
8	Demographic Factors Associated with Toxicity in Patients Treated with Anti–Programmed Cell Death-1 Therapy 2020 ·Cancer Immunology Research ·(unknown),Haocan Song,Fei Ye,Javid J. Moslehi,Justin M. Balko,Joe‐Elie Salem,Douglas B. Johnson	42
9	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance studybreakdown → 2019 ·Journal for ImmunoTherapy of Cancer ·Douglas B. Johnson,Ali Manouchehri,Alexandra M. Haugh,Henry T. Quach,Justin M. Balko,Bénédicte Lebrun‐Vignes,Andrew L. Mammen,Javid J. Moslehi,Joe‐Elie Salem	260
10	PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors 2017 ·Clinical Cancer Research ·Sarah Croessmann,Jonathan H. Sheehan,Kyung‐min Lee,Gregory Sliwoski,Jie He,Rebecca J. Nagy,David R. Riddle,Ingrid A. Mayer,Justin M. Balko,Richard B. Lanman,Vincent A. Miller,Lewis C. Cantley,Jens Meiler,Carlos L. Arteaga	27
11	Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade 2016 ·Molecular Cancer Research ·Michelle M. Williams,Linus Lee,Donna J. Hicks,Meghan M. Joly,David L. Elion,Bushra Rahman,(unknown),Violeta Sánchez,Justin M. Balko,Thomas Stricker,Mónica V. Estrada,Rebecca S. Cook	41
12	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer 2016 ·Cancer Research ·Katherine Amato,Shan Wang,Li Tan,Andrew K. Hastings,Wenqiang Song,Christine M. Lovly,Catherine B. Meador,Fei Ye,Lu Wang,Justin M. Balko,Daniel C. Colvin,Justin Cates,William Pao,Nathanael S. Gray,Jin Chen	84
13	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer 2014 ·Cancer Research ·Neil E. Bhola,Valerie M. Jansen,Sangeeta Bafna,Jennifer M. Giltnane,Justin M. Balko,Mónica V. Estrada,Ingrid M. Meszoely,Ingrid A. Mayer,Vandana G. Abramson,Fei Ye,Melinda E. Sanders,Teresa C. Dugger,Eliezer M. Van Allen,Carlos L. Arteaga	50
14	Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer 2013 ·Cancer Research ·Justin M. Balko,Luis J. Schwarz,Neil E. Bhola,Richard Kurupi,Philip Owens,Todd W. Miller,Henry Gómez,Rebecca S. Cook,Carlos L. Arteaga	122
15	Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer 2013 ·Clinical Cancer Research ·Jennifer B. Dennison,Jennifer R. Molina,Shreya Mitra,Ana M. González-Angulo,Justin M. Balko,María G. Kuba,Melinda E. Sanders,Joseph A. Pinto,Henry Gómez,Carlos L. Arteaga,Robert Brown,Gordon B. Mills	93
16	A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance 2011 ·Clinical Cancer Research ·Todd W. Miller,Justin M. Balko,Zara Ghazoui,Anita K. Dunbier,H Anderson,Mitch Dowsett,Ana M. González-Angulo,Gordon B. Mills,William R. Miller,Huiyun Wu,Yu Shyr,Carlos L. Arteaga	85
17	A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer 2011 ·Cancer Research ·Emily M. Fox,Todd W. Miller,Justin M. Balko,María G. Kuba,Violeta Sánchez,R. A. Smith,Shuying Liu,Ana M. González-Angulo,Gordon B. Mills,Fei Ye,Yu Shyr,H. Charles Manning,Elizabeth Buck,Carlos L. Arteaga	131
18	Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers 2011 ·Cancer Research ·Ritwik Ghosh,Archana Narasanna,Shizhen Emily Wang,Shuying Liu,Anindita Chakrabarty,Justin M. Balko,Ana M. González-Angulo,Gordon B. Mills,Elicia Penuel,John Winslow,Jeff Sperinde,Rajiv Dua,(unknown),Ali Mukherjee,Kim Leitzel,Wolfgang J. Köstler,Allan Lipton,Michael Bates,Carlos L. Arteaga	171
19	ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer 2011 ·Cancer Discovery ·Todd W. Miller,Justin M. Balko,Emily M. Fox,Zara Ghazoui,Anita K. Dunbier,H Anderson,Mitch Dowsett,Aixiang Jiang,R. A. Smith,Sauveur-Michel Maira,H. Charles Manning,Ana M. González-Angulo,Gordon B. Mills,Catherine Higham,(unknown),María G. Kuba,William R. Miller,Yu Shyr,Carlos L. Arteaga	241
20	Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature 2009 ·Cancer Biology & Therapy ·Justin M. Balko,Esther P. Black	2

About Justin M. Balko

Justin M. Balko is a scholar working on Oncology, Cancer Research and Immunology, having authored 152 papers that have together received 11.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (51 papers), Cancer Genomics and Diagnostics (28 papers) and PI3K/AKT/mTOR signaling in cancer (21 papers). The work is most often cited by research in Oncology (6.1k citations), Cancer Research (2.5k citations) and Immunology (2.7k citations). Justin M. Balko has collaborated with scholars based in United States, Peru and Australia. Frequent co-authors include Melinda E. Sanders, Ingrid A. Mayer, Douglas B. Johnson, Giampaolo Bianchini, Luca Gianni, Carlos L. Arteaga, Javid J. Moslehi, Todd W. Miller, Rebecca S. Cook and Caroline A. Nebhan. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact